Jiangsu Cowin Biotech Co (SHSE:688426) Cash-to-Debt : 27.56 (As of Mar. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Jiangsu Cowin Biotech Co Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Jiangsu Cowin Biotech Co's cash to debt ratio for the quarter that ended in Mar. 2024 was 27.56.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Jiangsu Cowin Biotech Co could pay off its debt using the cash in hand for the quarter that ended in Mar. 2024.

The historical rank and industry rank for Jiangsu Cowin Biotech Co's Cash-to-Debt or its related term are showing as below:

SHSE:688426' s Cash-to-Debt Range Over the Past 10 Years
Min: 8.54 Med: 14.99 Max: 36.62
Current: 27.56

During the past 6 years, Jiangsu Cowin Biotech Co's highest Cash to Debt Ratio was 36.62. The lowest was 8.54. And the median was 14.99.

SHSE:688426's Cash-to-Debt is ranked better than
67.6% of 1528 companies
in the Biotechnology industry
Industry Median: 6.315 vs SHSE:688426: 27.56

Jiangsu Cowin Biotech Co Cash-to-Debt Historical Data

The historical data trend for Jiangsu Cowin Biotech Co's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Jiangsu Cowin Biotech Co Cash-to-Debt Chart

Jiangsu Cowin Biotech Co Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

Get a 7-Day Free Trial

10.53

13.47

9.03

35.17

27.12

Jiangsu Cowin Biotech Co Quarterly Data
	Dec18	Dec19	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Cash-to-Debt	Get a 7-Day Free Trial											34.21	33.06	36.62	27.12	27.56

Competitive Comparison of Jiangsu Cowin Biotech Co's Cash-to-Debt

For the Biotechnology subindustry, Jiangsu Cowin Biotech Co's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Jiangsu Cowin Biotech Co's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Jiangsu Cowin Biotech Co's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Jiangsu Cowin Biotech Co's Cash-to-Debt falls into.

Jiangsu Cowin Biotech Co Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Jiangsu Cowin Biotech Co's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	893.623	/	(13.646	+	19.307)
	=	27.12

Jiangsu Cowin Biotech Co's Cash to Debt Ratio for the quarter that ended in Mar. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	850.561	/	(12.674	+	18.188)
	=	27.56

Jiangsu Cowin Biotech Co (SHSE:688426) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Jiangsu Cowin Biotech Co Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Jiangsu Cowin Biotech Co's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Jiangsu Cowin Biotech Co (SHSE:688426) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Jiangsu Cowin Biotech Co Ltd (SHSE:688426) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 1 Yaocheng Avenue, 4th Floor, TQB Building, Jiangsu Province, Taizhou, CHN, 225300

Website

https://www.cwbio.com

Jiangsu Cowin Biotech Co Ltd is a national high-tech enterprise with independent intellectual property rights based in the field of life sciences. It provides innovative biological products and services to in vitro diagnostic users. The product line mainly includes molecular diagnostic raw materials enzymes, nucleic acid collection and protection agents, nucleic acid extraction kits, molecular diagnostic detection reagents and others.

Executives

Yin Jian Feng	Director
Zhuang Zhi Hua	Directors, senior managers

Jiangsu Cowin Biotech Co (SHSE:688426) Headlines

No Headlines